Juteo

Tamsulosin hydrochloride and dutasteride, the active ingredients in Juteo, are an alpha‑1 adrenergic antagonist and a 5‑alpha‑reductase inhibitor presented as an oral tablet for oral use. It treats benign prostatic hyperplasia in adult men by improving urine flow and reducing prostate size. GNH USA supplies Juteo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juteo combines two agents that act on the prostate and lower urinary tract to manage benign prostatic hyperplasia and its symptoms. - Benign prostatic hyperplasia: relieves urinary obstruction and improves flow rate. - Lower urinary tract symptoms due to BPH: reduces urgency, frequency and nocturia. - Prostate enlargement: decreases prostate volume over time, helping to prevent disease progression.

Juteo may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Abnormal ejaculation or reduced libido. - Headache. - Nasal congestion or runny nose. - Orthostatic hypotension.

Serious or Rare Side Effects: - Intraoperative floppy iris syndrome during cataract surgery. - Severe hypotension requiring medical attention. - Allergic reactions such as rash, swelling or anaphylaxis. - Priapism (prolonged erection).

Before prescribing Juteo, clinicians should consider several safety measures. - Blood pressure monitoring: watch for orthostatic drops, especially after the first dose. - Hepatic function: adjust use in patients with moderate liver impairment. - Cataract surgery: inform surgeons of possible intraoperative floppy iris syndrome. - Concomitant alpha‑blockers: avoid additive hypotensive effects. - Prostate-specific antigen (PSA) testing: interpret results with caution as dutasteride lowers PSA levels. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Juteo can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other alpha‑1 adrenergic antagonists (e.g., prazosin) – risk of profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – increase dutasteride exposure. - Potent CYP2D6 inhibitors – may affect tamsulosin metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (e.g., ACE inhibitors, diuretics) – monitor blood pressure. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – may enhance hypotensive effect. - Non‑steroidal anti‑inflammatory drugs – increase risk of renal impairment with hypotension.